contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nextcell-pharma-ab-the-stem-cell-company-nextcell-invests-in-own-production-facility

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

NextCell Pharma operates in the healthcare sector. The company develops stem cell products that are mainly used in the treatment of autoimmune diabetes and kidney transplantation. A large part of the work consists of stem cell research where the company develops drug candidates that will facilitate and increase acceptance in organ transplantation. In addition, the company owns a stem cell bank. The company was founded in 2014 and has its headquarters in Huddinge.

Diamyd apparently owns about 15% of NextCell. Diamyd plummeted 90% today, and now there’s likely concern they’ll dump their NextCell shares due to a cash crunch. NextCell has dropped about 15% today. What are your thoughts on the situation? Is there also a slight worry creeping in about the viability of NextCell’s development pipeline?

Diabettech - Diabetes and Technology | Where Diabetes and Technology meet – 3 Mar 26              100% Insulin Independence: Why Eledon’s Breakthrough is a Pillar, Not a Cure...    Eledon Pharmaceuticals recently achieved 100% insulin independence in an early-phase islet transplant trial using its anti-CD40L drug, tegoprubart. It’s a massive step forward in transplant immunology that avoids the toxicity of standard drugs. But...

Results are out.  The report is still messy and incomplete. CEO comments are conspicuous by their absence, etc. This started in the previous quarterly report after the CFO left. Apparently, the new CFO has not fixed the issue. The report covers an exceptional 16-month financial year (September 2024 → December 2025) due to a change in the fiscal year, which makes direct comparison to previous years difficult. The company has admitted to this confusion and announced it will publish a separate comparison document to clarify the figures shortly after the report. Revenue from QVance does not yet appear to be recognized, which is a disappointment. This is in direct contradiction with the company’s comments that turnover would have accumulated since at least late summer. In practice, however, it seems that QVance’s sales are visible in the items Advances received and commitments (+1.1 MSEK, the parent company’s share of this growth was almost non-existent), Unbilled work and accrued income (increased by approx. 0.9 MSEK from a year ago), and Accounts receivable (increased by approx. 1M SEK at the point when QVance was said to have become operational). Although accounts receivable and advances point to some kind of operational activity, the company’s cash position fell to 26 million kronor by the end of 2025 (32.7 MSEK the previous year). This was influenced at least by QVance’s new isolator, which appears on the balance sheet likely as a 4.4 million kronor work-in-progress acquisition.             cdn.prod.website-files.com              699fe987c9e393af67bc206d_NextCell%20Bokslutskommunik%C3%A9%202024%202025%20SV.pdf    643.52 KB                            Edit: The CEO will comment on the quarter tonight: Digital temakväll - Life Science | Aktiespararna

The company is truly an extreme example of poor liquidity for a listed company. Last Friday at the open: 10:03 share 1.68 (+7%) 10:05 share 1.51 (-4%) Today the range was even wider. At the open, it rose +9.5%, and a couple of minutes later, it dipped to -5.5%. Hardly any trades were made; rather, this was most likely just the momentary spread of the share. Interested by this, I tried to figure out how large the actual float of the share is, assuming we count all “sticky money” (tahmainen raha)—meaning, in addition to insiders, long-term anchor investors, larger institutions, partners, etc. Instead of calculating it myself, I fed Gemini the insider transactions, key press releases, and the latest samples of the top 10 shareholders and debated for a while, correcting errors. Getting an exact figure is difficult because part of this rigid ownership is in nominee registers, and insider ownership is also held through separate holding/investment companies. Overall, it could be said that at least a good third (over 36%) of the company is somewhat “cemented,” meaning likely not active on the market (even though there are no legal barriers to selling). Optimistically, sticky money could amount to as much as 60 million shares, or about half, if we make a rough order-of-magnitude estimate of long-term investors from previous offerings. Whatever the “effective free float” is, it can generally be assumed to have decreased following the '25 subscription and the '26 direct investment, explaining the increased volatility to some extent. Additionally, a significant portion of retail investors’ NextCell positions are surely at the bottom of portfolios, 70%–90% in the red, and there is no interest in realizing those losses. The company’s record 1-month volume, which has only been broken in terms of share count by the recent Hong Kong news and the 2025 Pro-Young results announcement + rights issue, was set in September 2020 at a price over 10 times higher than the current one. In terms of euro value, those recent volumes fall far behind. Earnings release coming up on Thursday!

New press release and the stock is showing new momentum, up 12% today. For the sharp-eyed, however, this isn’t new information, because even though Nextcell hasn’t communicated this directly to investors, yours truly spotted this 29 days ago in this discussion.

Now the valuation has doubled, and rising revenue can, with some luck, justify it as well. Haven’t investors sufficiently accounted for the potential of these subsidiaries’ operations?  I don’t believe they’ve been given much weight, as not a single euro has been seen yet. The company’s small investor base is likely suffering from a major hangover after the previous -80% crash. The base case is probably still that the company’s value is primarily just a gamble on the success of the drug pipeline and partnerships, and a company that has been diluted for six years straight will likely be diluted for a seventh. Cellaviva has been a passive shell company owning cell banks, collecting the same fixed fees year after year without any growth, and that’s why Qvance isn’t being given much credit either. I should also include a quote from myself from the Diamyd thread:  In biotech, valuation doesn’t seem to be explained by rational probability calculations, but by certain kinds of hype cycles that fluctuate between the euphoria of early and intermediate stages and the nuclear winters caused by the despair of dilutions and long waiting periods.  Some calculating opportunists only jump into the gamble just before the results are released (like last year when the value tripled in a couple of months before the young-interim results). In small-cap biotech companies with low cash reserves, the price of the gamble while waiting for major drivers is directly proportional to the holding time and inversely proportional to the market cap, which is already incredibly small; the share count will inevitably increase significantly unless a “miracle” happens. The last offering was a disaster, and the company is also very little-known, and the researcher-led team hasn’t handled investor relations or the promotion of offerings well. Now, the pricing seems to assume that Nextcell will have to start share issuance procedures during the current year. Perhaps even before the readout. And with the market cap jumping between 7-15M, it would mean that the share price could soon be half of the current one before the most important driver is possible. However, the math of the expenses is in Nextcell’s favor. The costs are really low (someone could check how much Faron burns in Phase 2). So, even though losses are incurred, the specialized service operations—for which there is apparently no competition in the Nordics—might well turn the tide. Existing research staff and laboratory infrastructure can be used operationally and capital efficiently. Personally, I believe in this miracle—with the clarification that the whole company is unlikely to turn profitable immediately before the customer base opened up by the GMP license. However, the cash might easily be made to last past the readout without dilution. Those readouts are, along with partnerships, the ultimate big catalysts in this gamble. After the Phase 2 results, there are many uncertainties ahead, but the company has shown a smart business strategy and early limited market access is possible. There may be a wait ahead, but if the gamble doesn’t result in a loss while holding, then the expected value is positive. And yes, it could also be that this is indeed the company’s last resort, at least as an investment. If the new young-readout doesn’t improve at all from the previous “honeymoon” results, will there still be a willing financier for the adult Phase 3 or a buyer for the licenses? At the same time, Diamyd might reach Western markets first, and the Hong Kong route might turn out to be the only way to capture revenue before market saturation. Qvance might also be just a final desperate attempt to consolidate at least some value for the company and provide work for the researchers in case the phase readout fails. Well, whatever the case, I’m buying this gamble at least until the readout.

Interesting reflections and new perspectives. Nextcell’s cell therapy support businesses, Cellaviva and Qvance, are interesting during Nextcell’s current “valley phase” in terms of the liquidity that is crucial for the company. Cell therapies in general are evolving rapidly, and as an investor not intimately familiar with the field, one might think that support functions would be a growth area. Regarding Qvance’s future, I recall the group CEO mentioning that forecast I noted about Qvance’s profitability sometime late last year, albeit in passing. Qvance’s own CEO likely has better information. As mentioned earlier, when Nextcell’s valuation was at its lowest, €6-7m, a couple of months ago, it could be justified by this business alone. Its growth prospects provide peace of mind regarding the risk of total loss of investment typical for biotechs. Now the valuation has doubled, and with some luck, rising revenue can justify that too. Have investors not sufficiently factored in the potential of these subsidiaries? The other matter is the main event itself, Protrans. The interim readout in late summer is a make-or-break situation. If it fails, the downward spiral could be unstoppable. Based on the evidence so far, I consider the probability of success to be good. You brought up some interesting future plans for Nextcell. Speculation will have a more solid foundation in late summer after the interim readout.

NextCell Pharma

The stem cell company NextCell Pharma AB ("NextCell" or "the Company") announces today that they have entered into an agreement with the property manager Hemsö and the clean room supplier QleanAir...

The stem cell company NextCell Pharma AB ("NextCell" or "the Company") announces today that they have entered into an agreement with the property manager Hemsö and the clean room supplier QleanAir, to build a full-scale production facility. This new production facility will be directly connected to the Company's existing office and clean room in the Novum building, next to Karolinska University Hospital in Huddinge. The construction will take place later this spring and the premises are expected to be completed during the third quarter of 2021.The significant upcomming medical need for cellular therapeutics for diabetes and autoimmune diseases requires optimized large-scale production with locations in several manufacturing facilities. The production of NextCell's drug candidate ProTrans has from start been outsourced to PBKM FamiCord Group, also a strategic partner and shareholder in NextCell. By expanding the existing production capacity with its own GMP facility, NextCell further develops the manufacturing process from 2-dimensional cell culture to a 3-dimensional bioreactor in accordance with the Eurostars Horizon 2020 grant of SEK 5 million. NextCell's establishment of the new full-scale GMP facility is key in the bioreactor manufacturing process development as the primary purpose of the GMP facility is to prepare technology transfer to a potential partner or additional contract manufacturer in addition to the PBKM FamiCord Group.We have made tremendous progress and it is time to consolidate the selection algorithm and the manufacturing process. Prior to market approval, we must ensure the availability of ProTrans. With its own GMP facility, NextCell is taking the first step towards securing future production on a commercial scale", says Mathias Svahn, CEO of NextCell.NextCell already has D-class clean rooms, a permit to operate a tissue establishment, a biobank with a primary sample collection and a wholesale permit in accordance with GDP issued by IVO and the Medical Products Agency. The new premises will house GMP-certified B-class cleanrooms and a QC laboratory that can be used for process development and ProTrans production, after the usual permit testing by the Swedish Medical Product Agency.